CO5700783A2 - Uso de b7-h3 como un agente inmuno regulatorio - Google Patents
Uso de b7-h3 como un agente inmuno regulatorioInfo
- Publication number
- CO5700783A2 CO5700783A2 CO05116756A CO05116756A CO5700783A2 CO 5700783 A2 CO5700783 A2 CO 5700783A2 CO 05116756 A CO05116756 A CO 05116756A CO 05116756 A CO05116756 A CO 05116756A CO 5700783 A2 CO5700783 A2 CO 5700783A2
- Authority
- CO
- Colombia
- Prior art keywords
- agonist
- domain
- soluble form
- lymphocyte
- regulatory immune
- Prior art date
Links
- 230000001105 regulatory effect Effects 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 210000004698 lymphocyte Anatomy 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Un método para inhibir la activación de un linfocito, el método comprende poner en contacto el linfocito con un agonista B7-H3 y permitir al agonista inhibirla activación del linfocito.2.- El método según la reivindicación 1, en donde el agonista B7-H3 es una forma soluble de B7-H3.3.- El método según la reivindicación 3, en donde elagonista B7-H3 comprende la ID DE SEC. NO.: 15.4.- El método según la reivindicación 2, en donde laforma soluble comprende al menos un dominio V de B7-H3.5.- El método según la reivindicación 4, en donde el dominio V comprende: (a) la ID DE SEC. NO.: 7 o (b) una secuencia de aminoácido que es sustancialmente idéntica a la ID DE SEC. NO.: 7.6.- El método según la reivindicación 4, en donde laforma soluble de B7-H3 comprende además al menos undominio C de B7-H3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46334203P | 2003-04-17 | 2003-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5700783A2 true CO5700783A2 (es) | 2006-11-30 |
Family
ID=33310770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05116756A CO5700783A2 (es) | 2003-04-17 | 2005-11-17 | Uso de b7-h3 como un agente inmuno regulatorio |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050002935A1 (es) |
EP (1) | EP1620119A2 (es) |
JP (2) | JP2006523711A (es) |
KR (1) | KR20060017496A (es) |
CN (1) | CN1809370A (es) |
AU (1) | AU2004231748A1 (es) |
BR (1) | BRPI0409476A (es) |
CA (1) | CA2521847A1 (es) |
CO (1) | CO5700783A2 (es) |
MX (1) | MXPA05011050A (es) |
NO (1) | NO20054790L (es) |
RU (1) | RU2005135739A (es) |
WO (1) | WO2004093894A2 (es) |
ZA (1) | ZA200508367B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP1292619B1 (en) | 2000-06-06 | 2008-02-06 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
EP1577323B1 (en) | 2002-12-26 | 2013-07-10 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
PE20091567A1 (es) | 2004-06-25 | 2009-11-03 | Takeda Pharmaceutical | Derivados de metastina en el tratamiento del cancer |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
CA2668800A1 (en) * | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7 and antibodies that bind thereto |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
PE20170779A1 (es) | 2010-03-04 | 2017-07-04 | Macrogenics Inc | Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos |
KR102030987B1 (ko) * | 2011-04-25 | 2019-11-11 | 다이이찌 산쿄 가부시키가이샤 | 항 b7-h3항체 |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
MX2016010505A (es) | 2014-02-14 | 2017-04-13 | S Chi Andrew | Metodos mejorados para el tratamiento de canceres vascularizantes. |
RU2731202C2 (ru) | 2015-10-08 | 2020-08-31 | Макродженикс, Инк. | Комбинированная терапия для лечения рака |
UA127341C2 (uk) | 2016-04-15 | 2023-07-26 | Мекроудженікс, Інк. | Виділена b7-н3-зв'язувальна молекула |
US10899837B2 (en) * | 2017-03-31 | 2021-01-26 | Jiangsu Hengrui Medicine Co., Ltd. | B7-H3 antibody, antigen-binding fragment thereof and medical use thereof |
CN109097366A (zh) * | 2017-06-21 | 2018-12-28 | 黄海东 | 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用 |
CN112239502A (zh) * | 2019-07-18 | 2021-01-19 | 上海复旦张江生物医药股份有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
CA3124721A1 (en) * | 2018-12-24 | 2020-07-02 | Xiaoyi Zhou | Recombinant human 21g-b7-h3 protein coding gene, recombinant vector, host cell comprising the same, pharmaceutical composition and use thereof |
CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技(成都)有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
CN111088227A (zh) * | 2019-12-31 | 2020-05-01 | 广州航华生物医药科技有限公司 | 一种细胞分离培养液和t细胞分离培养的方法 |
US20240108745A1 (en) | 2021-02-09 | 2024-04-04 | Medilink Therapeutics (Suzhou) Co., Ltd. | Bioactive substance conjugate, preparation method therefor and use thereof |
CN113144181B (zh) * | 2021-04-20 | 2022-07-19 | 徐州医科大学 | 一种靶向b7h3的dna疫苗、制备方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1292619B1 (en) * | 2000-06-06 | 2008-02-06 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
WO2002010187A1 (en) * | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
US20040236088A1 (en) * | 2001-08-02 | 2004-11-25 | Heuer Josef Georg | Novel polypeptide analogs and fusions and their methods of use |
-
2004
- 2004-04-15 US US10/824,481 patent/US20050002935A1/en not_active Abandoned
- 2004-04-16 CA CA002521847A patent/CA2521847A1/en not_active Abandoned
- 2004-04-16 MX MXPA05011050A patent/MXPA05011050A/es not_active Application Discontinuation
- 2004-04-16 EP EP04750222A patent/EP1620119A2/en not_active Withdrawn
- 2004-04-16 WO PCT/US2004/011767 patent/WO2004093894A2/en active Application Filing
- 2004-04-16 KR KR1020057019786A patent/KR20060017496A/ko not_active Application Discontinuation
- 2004-04-16 CN CNA2004800170492A patent/CN1809370A/zh not_active Withdrawn
- 2004-04-16 BR BRPI0409476-0A patent/BRPI0409476A/pt not_active IP Right Cessation
- 2004-04-16 RU RU2005135739/13A patent/RU2005135739A/ru not_active Application Discontinuation
- 2004-04-16 AU AU2004231748A patent/AU2004231748A1/en not_active Abandoned
- 2004-04-16 JP JP2006510118A patent/JP2006523711A/ja not_active Withdrawn
-
2005
- 2005-10-14 ZA ZA200508367A patent/ZA200508367B/en unknown
- 2005-10-18 NO NO20054790A patent/NO20054790L/no not_active Application Discontinuation
- 2005-11-17 CO CO05116756A patent/CO5700783A2/es not_active Application Discontinuation
-
2007
- 2007-03-30 JP JP2007095108A patent/JP2007191489A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NO20054790L (no) | 2005-11-16 |
EP1620119A2 (en) | 2006-02-01 |
WO2004093894A3 (en) | 2005-03-24 |
BRPI0409476A (pt) | 2006-05-02 |
ZA200508367B (en) | 2007-04-25 |
MXPA05011050A (es) | 2006-03-17 |
KR20060017496A (ko) | 2006-02-23 |
AU2004231748A1 (en) | 2004-11-04 |
CN1809370A (zh) | 2006-07-26 |
WO2004093894A8 (en) | 2005-05-19 |
WO2004093894A2 (en) | 2004-11-04 |
CA2521847A1 (en) | 2004-11-04 |
NO20054790D0 (no) | 2005-10-18 |
JP2007191489A (ja) | 2007-08-02 |
JP2006523711A (ja) | 2006-10-19 |
RU2005135739A (ru) | 2006-03-20 |
US20050002935A1 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5700783A2 (es) | Uso de b7-h3 como un agente inmuno regulatorio | |
ES2542853T3 (es) | Método para tratar miastenia grave | |
ES2619332T3 (es) | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma | |
AR020442A1 (es) | Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma | |
CL2022001670A1 (es) | Inhibidores de proteínas kras mutantes | |
CY1121580T1 (el) | ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
WO2022155530A8 (en) | Variant strain-based coronavirus vaccines | |
ECSP16012693A (es) | Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y polipéptido que contiene aditivo, uso y procedimiento de los mismos | |
ES2689746T3 (es) | Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer | |
ES2111710T3 (es) | Proteasas que inhiben y desprenden el biofilm. | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
DK0897726T3 (da) | Antipruritisk middel | |
AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
CL2008002847A1 (es) | Composicion de catalizador que comprende el producto del contacto entre un ansa-metaloceno y un activador; metodo para polimerizar olefinas; y ansa-metaloceno. | |
AR059667A1 (es) | Montaje de desgaste | |
DK1297013T3 (da) | Anvendelse af TACI som antitumormiddel | |
CO6440573A2 (es) | Agentes tensoactivos viscoelásticos y métodos para la elaboración y uso de los mismos | |
EA201000327A1 (ru) | Белок | |
CL2004000959A1 (es) | Metodo para elaborar un aceite que comprende en alimentar un pez con una composicion que comprende acido araquidonico y extraer un aceite que comprende al menos 2% en peso de acido araquidonico desde dicho pez, aceite de pescado y su uso. | |
DK0985675T3 (da) | Hydrosilaniseringsfremgangsmåde med höjt udbytte | |
CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
DE602006017705D1 (de) | Zytotoxische ribonukleasevarianten | |
ATE255558T1 (de) | Verfahren zur herstellung von alkylierten diphenylaminzusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |